Protein-Ligand Interactions: Target Identification and Drug Discovery
Bioactive compounds and drugs are designed and screened on the basis of specific molecular targets as well as via the identification of active ingredients from traditional medicine or by serendipitous discovery. The development of novel therapeutic strategies not only requires a deep knowledge of th...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_76609 | ||
005 | 20220111 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220111s2021 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-1051-4 | ||
020 | |a 9783036510507 | ||
020 | |a 9783036510514 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-1051-4 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PN |2 bicssc | |
100 | 1 | |a Altieri, Fabio |4 edt | |
700 | 1 | |a Altieri, Fabio |4 oth | |
245 | 1 | 0 | |a Protein-Ligand Interactions: Target Identification and Drug Discovery |
260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
300 | |a 1 electronic resource (184 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Bioactive compounds and drugs are designed and screened on the basis of specific molecular targets as well as via the identification of active ingredients from traditional medicine or by serendipitous discovery. The development of novel therapeutic strategies not only requires a deep knowledge of the molecular processes and the cellular pathways involved in each pathological condition and disease, but also the specific protein targets and the effects of drug binding on protein conformation and activity. Understanding of how drugs can modify and modulate specific cellular pathways and functions will be helpful during the process of drug development and clinical trials. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Chemistry |2 bicssc | |
653 | |a serum half-life extension | ||
653 | |a fatty acid conjugation | ||
653 | |a FcRn-mediated recycling | ||
653 | |a serum albumin | ||
653 | |a translocator protein (TSPO) | ||
653 | |a CoCl2 | ||
653 | |a mitochondrial membrane potential | ||
653 | |a reactive oxygen species (ROS) | ||
653 | |a cell viability | ||
653 | |a cell death | ||
653 | |a lung cancer cell line | ||
653 | |a acetylcholinesterase | ||
653 | |a amyloid beta aggregation | ||
653 | |a neuroprotection | ||
653 | |a molecular docking | ||
653 | |a multi-target drug | ||
653 | |a structure-activity relationship | ||
653 | |a brassicasterol | ||
653 | |a phytosterols | ||
653 | |a HSV | ||
653 | |a Mycobacterium tuberculosis | ||
653 | |a HSV-1 DNA polymerase | ||
653 | |a HSV-1 TK | ||
653 | |a human CDK2 | ||
653 | |a ACE | ||
653 | |a UDP-galactopyranose mutase | ||
653 | |a heat shock protein 70 | ||
653 | |a Hsp70 | ||
653 | |a piperine | ||
653 | |a fluorescence spectroscopy | ||
653 | |a molecular dynamics | ||
653 | |a molecular biophysics | ||
653 | |a GADD45β | ||
653 | |a MKK7 | ||
653 | |a multiple myeloma | ||
653 | |a protein-ligand interaction | ||
653 | |a STD-NMR | ||
653 | |a sigma receptors | ||
653 | |a sigma ligands | ||
653 | |a cancer | ||
653 | |a SIGMAR1 | ||
653 | |a PGRMC1 | ||
653 | |a TMEM97 | ||
653 | |a NCI60 COMPARE analysis | ||
653 | |a membrane | ||
653 | |a lipid-protein interaction | ||
653 | |a lipid signalling | ||
653 | |a kinase regulation | ||
653 | |a phosphatidylinositols | ||
653 | |a molecular docking simulation | ||
653 | |a target identification | ||
653 | |a small-molecule derivatives of salicylanilide | ||
653 | |a drug discovery | ||
653 | |a drug development | ||
653 | |a thyroid diseases | ||
653 | |a endocrine disruptor compound | ||
653 | |a human umbilical artery | ||
653 | |a vascular homeostasis | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4054 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/76609 |7 0 |z DOAB: description of the publication |